

## **An ultra-sensitive, ultra-fast whole blood monocyte CD169 assay for COVID-19 screening**

Moïse Michel<sup>1,2\*#</sup>, Fabrice Malergue<sup>3\*</sup>, Inès Ait Belkacem<sup>3</sup>, Pénélope Bourgoïn<sup>3</sup>, Pierre-Emmanuel Morange<sup>4</sup>, Isabelle Arnoux<sup>4</sup>, Tewfik Miloud<sup>3</sup>, Matthieu Million<sup>1,2</sup>, Hervé Tissot-Dupont<sup>2</sup>, Jean-Louis Mege<sup>1,2</sup>, Jean-Marc Busnel<sup>3</sup>, Joana Vitte<sup>1,2</sup>

1 Aix-Marseille Univ, IRD, APHM, MEPHI, Marseille, France

2 IHU Méditerranée Infection, Marseille, France

3 Beckman Coulter, Marseille, France

4 C2VN Aix Marseille Univ INSERM, INRAE, APHM Hôpitaux Universitaires de Marseille, Hôpital Timone, Service d'hématologie, Marseille, France

*\* MM and FM contributed equally to the paper*

### **# Corresponding author:**

Dr. Moïse Michel

Unité d'immuno-allergologie

IHU Méditerranée Infection

19-21 boulevard Jean Moulin

13005 Marseille, France

moise0michel@gmail.com

Phone : +33413732051

**Number of words:** 3,350 / 4,000

**Number of figures:** 3

**Number of tables:** 1

**Conflict of interest:** TM, JMB, IAB, PB and FM are employees of Beckman Coulter Life Sciences. JV has received speaker and consultancy fees from Meda Pharma, Mylan, Sanofi, Thermo Fisher, Beckman Coulter, outside this work. The other authors declare no conflict of interest related to this work.

**Abstract:**

CoVID-19 is an unprecedented epidemic, globally challenging health systems, societies, and economy. Its diagnosis relies on molecular methods, with drawbacks revealed by current use as mass screening. Monocyte CD169 upregulation has been reported as a marker of viral infections, we evaluated a flow cytometry three-color rapid assay of whole blood monocyte CD169 for CoVID-19 screening.

Outpatients (n=177) with confirmed CoVID-19 infection, comprising 80 early-stage ( $\leq 14$  days after symptom onset), 71 late-stage ( $\geq 15$  days), and 26 asymptomatic patients received whole blood CD169 testing in parallel with SARS-CoV-2 RT-PCR. Upregulation of monocyte CD169 without polymorphonuclear neutrophil CD64 changes was the primary endpoint. Sensitivity was 98% and 100% in early-stage and asymptomatic patients respectively, specificity was 50% and 84%. Rapid whole blood monocyte CD169 evaluation was highly sensitive when compared with RT-PCR, especially in early-stage, asymptomatic patients whose RT-PCR tests were not yet positive.

Diagnostic accuracy, easy finger prick sampling and minimal time-to-result (15-30 minutes) rank whole blood monocyte CD169 upregulation as a potential screening and diagnostic support for CoVID-19.

Secondary endpoints were neutrophil CD64 upregulation as a marker of bacterial infections and monocyte HLA-DR downregulation as a surrogate of immune fitness, both assisting with adequate and rapid management of non-CoVID cases.

**Number of words:** 199 / 200

## 1 **Introduction**

2 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), causing coronavirus disease 2019 (CoVID-  
3 19) is a historic global epidemic that continues to spread one year after having emerged (1). Its control  
4 requires targeted protection, distancing, and isolation. Aiming at selective isolation of subjects with a  
5 confirmed infection, a policy of massive diagnostic testing has been put in place in many countries. Ideally,  
6 this should allow any person to receive a prompt and straightforward answer at the time of symptom  
7 onset or contact tracing. This diagnosis is essentially based on molecular (reverse transcriptase-  
8 polymerase chain reaction (RT-PCR)) tests that detect viral RNA in a sample taken from the back of the  
9 nose or throat. Despite being the gold standard, RT-PCR has limitations. Firstly, the sensitivity is not  
10 optimal (2), mainly due to sampling quality and to the delay between contamination and colonization of  
11 the upper ear, nose, and throat area. Patients may receive a false negative result putting those around  
12 them at risk. Secondly, although RT-PCR is a fairly fast technique (1 to a few hours), laboratory saturation  
13 due to massive screening policies is leading to significant delays in sampling, processing, and result  
14 delivery, which may directly jeopardize distancing policies or unnecessarily hinder social and professional  
15 activity. Thirdly, deep nasal swabbing is unpleasant for the patient and potentially dangerous for the  
16 sampler. Finally, RT-PCR remains quite expensive. As a result and while massive testing is a required pillar  
17 for the fight against the pandemic, considerable efforts are made in search of efficient diagnostic aid  
18 solutions for mass testing strategies.

19 Antigenic tests of viral proteins are cheaper than RT-PCR, faster, and some can be performed on salivary  
20 samples that are easier to access and allow testing at home. However, their sensitivity is low, especially  
21 when using saliva instead of a nasal swab (3, 4). On the other hand, serological tests do not inform on  
22 actual carriage of the virus, are positive at least one week post-infection and lack sensitivity (5).

23 In this context, harnessing immune markers of leukocyte activation is a promising tool. Indeed, leukocytes  
24 detect and rapidly respond to infection with secreted and surface activation molecules. We and others  
25 have previously reported that acute viral infections induce the appearance of CD169 (Siglec-1,  
26 sialoadhesin) at the surface of blood monocytes (6, 7). Monocyte CD169 expression is upregulated by type  
27 1 interferons (8), produced by locally attacked tissues, and is found in all circulating blood monocytes,  
28 allowing its detection in minimal blood volumes such as a drop of blood at the fingertip. CD169  
29 upregulation has been found in patients with HIV (9), EBV (10), RSV (11), CMV (12), Dengue (13, 14), Zika  
30 (15), noroviruses (16), Lassa and Marburg (17). Transcriptomic and mass cytometry studies have identified  
31 CD169 as a relevant biomarker for CoVID-19 (18, 19). The first evaluation by flow cytometry on patients  
32 not only confirmed CD169 as a SARS-CoV-2 infection marker, but also showed that its expression was  
33 much higher than for any other virus tested so far (20, 21).

34 Having developed a rapid (15 min) and affordable assay to measure monocyte CD169 upregulation in a  
35 few microliters of blood (22), we set out to assess its diagnostic efficacy in a large cohort of CoVID-19-  
36 confirmed patients, with SARS-CoV-2 RT-PCR as the reference method. This assay evaluated in parallel  
37 two other immune markers: upregulation of CD64 on polymorphonuclear neutrophils, which is widely  
38 used as an indicator of bacterial infection (23), and expression of HLA-DR on monocytes, which reflects  
39 the general state of the immune system (24): increased when activated by a pathogen (viral or bacterial),  
40 and decreased if the immune system is "exhausted" by a severe infection (e.g. sepsis).

## 41 Results and Discussion

42 On the basis of the clinical and laboratory results, the 177 RT-PCR-confirmed SARS-CoV-2 patients were  
43 sorted into 3 groups: patients who presented at an early stage of the disease (less than 14 days after  
44 symptoms onset, n=80, group 1), those at a later stage of the disease (with a median of 19 days after  
45 symptoms onset (range 14-48), n=71, group 2), and asymptomatic patients (n=26, group 3). In each group,  
46 patients were further separated according to the concomitant RT-PCR results (**Figure 1**).

47 CD169 expression was significantly higher in groups 1 and 3 as compared to group 2, with a median index  
48 of 17 (range 2.1-46.0, interquartile range IQR 4-31) and 2.8 (range 1.7-43.0, IQR 2.3-18.8) versus 2.3 (range  
49 1.7-20.0, IQR 2.1-2.6),  $p < 0.001$ . Using the previously established threshold of 3.5 for CD169 index (20), we  
50 observed that 23/25 (92%) healthy controls samples obtained from the blood bank were negative, with 2  
51 outliers.

52 In the first group of CoVID-19 patients (early stage), the CD169 index was higher than the 3.5 threshold in  
53 80% of patients (64/80) (**Figure 1A**), while concomitant RT-PCR detected the virus (new cases), or  
54 confirmed it (re-tested cases), in 65% of patients (52/80). Among the 16 CD169-negative early-stage  
55 patients, 15 also had a negative concomitant RT-PCR. Sensitivity was 98%, with one patient exhibited a  
56 CD169 index below the threshold but a positive nasopharyngeal RT-PCR in the swab. Review of laboratory  
57 data for this patient showed very low and decreasing RNA quantities (cycle threshold (Ct) at 34.5 and 33.5,  
58 respectively 24 and 48 hours earlier), suggesting a near complete viral clearance. In line with this  
59 observation, the 15 other CD169 negative samples had been collected 6 to 14 days after the onset of  
60 symptoms, and the corresponding RT-PCR were also negative. Thus, sensitivity of monocyte CD169 was  
61 98% when compared to RT-PCR.

62 In the second group (late stage), CD169 and RT-PCR were positive in only 7% of patients (5/71), in which  
63 the RT-PCR were negative (**Figure 1B**), indicating that CD169 expression returns to baseline levels upon  
64 viral clearance.

65 In the third group (asymptomatic cases), significant CD169 upregulation was detected in 46% of patients  
66 (12/26), at levels similar to those of group 1 comprising recent infections (**Figure 1C**), while concomitant  
67 RT-PCR was positive in 35% of patients (9/26). All nine PCR positive cases were detected unambiguously.  
68 It is remarkable that almost half of asymptomatic patients, who made up 15% of the study cohort,  
69 expressed CD169 at the same level as patients experiencing symptoms. Indeed, the area under the curve  
70 (AUC) and overall performances, as displayed in **Figure 1D**, were similar for groups 1 and 3 (AUC at 0.93  
71 and 0.95; sensitivity at 98 and 100 %; specificity at 50 and 82 %; positive predictive value (PPV) at 78 and  
72 75 %; negative predictive value (NPV) at 93 and 100%, respectively for group 1 and 3) while CD169 index  
73 did not display good performance for patient with late stage disease (AUC at 0.58).

74 These findings suggest that despite the absence of symptoms, a systemic response orchestrating infection  
75 control takes place, rather than a purely local control of the infection (resistant tissue and/or tissue  
76 immunity).

77 There was only a weak correlation between CD169 level and RT-PCR Ct (**Figure 2**). Still, the few CD169  
78 negative patients were found among the weakest RT-PCR Ct.

79 Neutrophil CD64 expression, a marker of bacterial infections, was unchanged in 75% of the cases and  
80 weakly upregulated in 25% of the cases (45/177), showing no significant differences between groups (23,  
81 27, and 31% respectively). Within this cohort of outpatients presenting with mild disease, HLA-DR was  
82 expressed at normal or slightly increased levels, an expected finding as opposed to the decrease usually  
83 observed in severe cases(25). (**Figure 3**).

84 The sensitivity of monocyte CD169 upregulation was almost equivalent to RT-PCR for early-stage patients  
85 and asymptomatic patients. There was a high percentage (80%) of positive CD169 results in early-stage  
86 patients, peaking at 98.5% during the first week. As exemplified by these cases, false negative RT-PCR has  
87 a frequent occurrence, in agreement with the commonly described false negative rates ranging from 10  
88 to 30%(5).

89 Considering the main screening target, *i.e.*, recent symptomatic cases (within 7 days) with a positive RT-  
90 PCR the same day (n=49) or less than 48 h prior to or following CD169 assessment (n=54), 98.5% were  
91 identified through monocyte CD169 upregulation, with an unambiguous median index of 22.

92 Monocyte CD169 upregulation as a specific marker of viral infection was previously shown to outperform  
93 routine biomarkers (C-reactive protein, leukocyte counts, etc.). Indeed, CD169 elevation is restricted to  
94 acute viral infection(20). Virological identification of the culprit species, *i.e.* SARS-CoV-2 RT-PCR, remains  
95 necessary. Data obtained in the present study demonstrate that a testing strategy leveraging monocyte  
96 CD169 upregulation as a triage test could be designed. Taking into account the sensitivity of the assay and  
97 the current positivity rate of RT-PCR tests, ranging from 1 to 10%, a CD169-based screening could help  
98 prioritize true positives by a factor of 10 to 100, thereby opening the perspective to decrease the pressure  
99 currently observed on the health system.

100 Further advantages of monocyte CD169 assay are: 1. Better sensitivity that reduces or avoids false  
101 negative results. 2. Finger prick or venous blood sampling (easier, less painful, less dangerous, and without  
102 risk of failure). 3. A rapid result (15 minutes) allowing an immediate response to the consultation. 4.  
103 Affordable reagents and lighter logistics. 5. Not using a closed system, as the assay is supported by most  
104 flow cytometers equipping clinical laboratories.

105 Screening for monocyte CD169 upregulation could alleviate the load on specialized RT-PCR services and  
106 reduce overall costs, while making the sample collection step easier for the greatest number of people.

107 One can even consider solutions where tests are performed at home and then sent to central laboratories  
108 by mail or carrier, since this antibody cocktail can be unitized and dried in tubes in a ready to use format  
109 stable at room temperature (Duraclone technology®, Beckman-Coulter Life Sciences).

110 From a more fundamental standpoint, considering the close relationship between type I interferon based  
111 signaling and monocyte CD169 expression, the latter marker could be employed as a surrogate for this  
112 cytokine family. If so, in the light of recent publications(26, 27) demonstrating the critical role of type I  
113 interferons in viral infections in general and in CoVID-19 in particular, rapid assessment of monocyte  
114 CD169 upregulation could help stratify patients and identify those at higher risk of developing more severe  
115 forms of COVID-19.

116 Combined detection of monocyte CD169 for viral infections, neutrophil CD64 for bacterial infections, and  
117 monocyte HLA-DR for immune status allows the referral of non-CoVID-19 cases to an adequate and rapid  
118 management. Moreover, the variety of neutrophil CD64 and monocyte HLA-DR levels observed in CoVID-  
119 19 patients may help identify patients at risk for developing more severe disease. This hypothesis would  
120 deserve a larger and longitudinal study.

121 The main strengths of this study are its outpatient design, its large sample size and the confirmation of  
122 SARS-CoV-2 infection with multiple RT-PCR. However, performing the comparison in real screening  
123 settings (finger pricks instead of venous blood) would provide further confirmation on the performance  
124 of the proposed assay. Prospective studies fulfilling this criterion and including further categories of  
125 patients (pediatric, comorbidities) are now required to fully assess the capabilities and possible  
126 limitations of this assay.



## 127 **Methods**

128 *Samples:* This non-interventional study was conducted in the immunology laboratory of the  
129 IHU Méditerranée Infection (Assistance Publique – Hôpitaux de Marseille, Marseille, France) on leftover  
130 samples from 177 consecutive patients aged 16 or older with RT-PCR-confirmed SARS-CoV-2 infection (at  
131 least one positive SARS-CoV-2 RT-PCR in nasopharyngeal swabs or tracheal aspiration).

132 Blood samples used in the flow cytometry study were obtained from patients being either first  
133 presentations, patients re-tested after a positive test in another laboratory, or positive patients re-tested  
134 during the clinical follow-up of the infection. Each patient was tested in parallel with a “concomitant RT-  
135 PCR” on the same day. Demographic, clinical and laboratory data including date of onset of SARS-CoV-2-  
136 related symptoms were collected for each patient retrospectively from electronic medical records.

137 Samples of healthy blood donors (HBD) group served as controls (Convention N°7828, “Etablissement  
138 Français du Sang”, Marseille, France)

139 The study was approved by the institutional ethics and GDPR committee, with the reference number  
140 PJ4BQH. According to French law, the patients were informed and retained the right to oppose the use of  
141 their anonymized medical data for research purposes, but formal consent was not required for this non-  
142 interventional study.

143

### 144 *Flow cytometry*

145 All antibodies and reagents were from Beckman-Coulter Life Sciences (Marseille, France). Leftover EDTA-  
146 anticoagulated samples were maintained at room temperature for a maximum of 24 hours prior to flow  
147 cytometry investigations. The 3 specific antibodies were pre-mixed in a ready-to-use cocktail (prototype  
148 of the IOTest Myeloid Activation CD169-PE/HLA-DR-APC/CD64-PacBlue Antibody Cocktail, Beckman  
149 Coulter Life Sciences). The cocktail was then pre-mixed with 0.5 mL of Versalyse RBC lysing solution, and  
150 10 µL of blood were added in the reaction tube. The mixture was finally mixed manually. After 10 minutes

151 incubation at room temperature, the samples were analyzed 1 minute on a routine 3 laser Navios flow  
152 cytometer from Beckman Coulter Life Sciences (Miami, USA).

153

154 *Data analysis and statistics*

155 Flow cytometry data files were analyzed using the Kaluza software, version 2.1 (Beckman Coulter Life  
156 Sciences). Leukocytes were gated using Side Scatter (SSC) and CD64 expression as lymphocytes (low SSC  
157 CD64-), monocytes (intermediate SSC CD64+), and neutrophils (high SSC), prior to the analysis of CD169,  
158 CD64 and HLA-DR level of expression. The CD169 index was calculated as the ratio of CD169 expression  
159 on monocyte vs CD169 expression on lymphocyte (background) signal. Similarly, the CD64 index was  
160 calculated as the ratio of neutrophil versus lymphocyte signal. Data were exported to JMP 14.2.0 software  
161 (SAS) for statistical analysis. Mean index values of each group were compared via Student's or Kruskal-  
162 Wallis tests as appropriate. A two-sided p-value < 0.05 was considered statistically significant.


163 **Author contributions:** JV, TM and PEM designed the study. MoM, IAB and FM conducted experiments and  
164 acquired data. MaM and HTD supervised clinical procedures. MoM collected and analyzed demographic,  
165 clinical and laboratory data. PB and FM provided antibody panels and PEM and IA the flow cytometry  
166 platform. MoM, FM, and JMB analyzed experimental data. FM, MoM, JMB, and JV wrote the manuscript.  
167 JLM revised the manuscript for important intellectual content. All authors read and approved the final  
168 manuscript.

169 **References**

- 170 1. Zhu N et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. *N. Engl. J. Med.*  
171 2020;382(8):727–733.
- 172 2. Woloshin S, Patel N, Kesselheim AS. False Negative Tests for SARS-CoV-2 Infection — Challenges and  
173 Implications. *N. Engl. J. Med.* 2020;383(6):e38.
- 174 3. Freeman B et al. Validation of a SARS-CoV-2 spike protein ELISA for use in contact investigations and  
175 serosurveillance [Internet]. *bioRxiv* [published online ahead of print: April 25, 2020];  
176 doi:10.1101/2020.04.24.057323
- 177 4. Han P, Ivanovski S. Saliva—Friend and Foe in the COVID-19 Outbreak [Internet]. *Diagnostics*  
178 2020;10(5). doi:10.3390/diagnostics10050290
- 179 5. Miller TE et al. Clinical sensitivity and interpretation of PCR and serological COVID-19 diagnostics for  
180 patients presenting to the hospital. *FASEB J.* 2020;fj.202001700RR.
- 181 6. Bourgoin P et al. Clinical research assessment by flow cytometry of biomarkers for infectious  
182 stratification in an Emergency Department. *Biomark. Med.* 2019;13(16):1373–1386.
- 183 7. Bourgoin P et al. Flow cytometry evaluation of infection-related biomarkers in febrile subjects in the  
184 emergency department. *Future Microbiol.* 2020;15:189–201.
- 185 8. Bourgoin P, Biéché G, Ait Belkacem I, Morange P, Malergue F. Role of the interferons in CD64 and  
186 CD169 expressions in whole blood: Relevance in the balance between viral- or bacterial-oriented  
187 immune responses. *Immun. Inflamm. Dis.* 2020;8(1):106–123.
- 188 9. van der Kuyl AC et al. Sialoadhesin (CD169) expression in CD14+ cells is upregulated early after HIV-1  
189 infection and increases during disease progression. *PLoS One* 2007;2(2):e257.
- 190 10. Farina A et al. Epstein-Barr virus lytic infection promotes activation of Toll-like receptor 8 innate  
191 immune response in systemic sclerosis monocytes. *Arthritis Res. Ther.* 2017;19(1):39.
- 192 11. Jans J et al. Siglec-1 inhibits RSV-induced interferon gamma production by adult T cells in contrast to  
193 newborn T cells. *Eur. J. Immunol.* 2018;48(4):621–631.

- 194 12. Theobald SJ et al. Signatures of T and B Cell Development, Functional Responses and PD-1  
195 Upregulation After HCMV Latent Infections and Reactivations in Nod.Rag.Gamma Mice Humanized With  
196 Cord Blood CD34+ Cells. *Front. Immunol.* 2018;9:2734.
- 197 13. Green AM, Harris E. Monocyte-Plasmablast Crosstalk during Dengue. *Cell Host Microbe*  
198 2014;16(1):7–9.
- 199 14. Kwissa M et al. Dengue Virus Infection Induces Expansion of a CD14+CD16+ Monocyte Population  
200 that Stimulates Plasmablast Differentiation. *Cell Host Microbe* 2014;16(1):115–127.
- 201 15. Hirsch AJ et al. Zika Virus infection of rhesus macaques leads to viral persistence in multiple tissues.  
202 *PLOS Pathog.* 2017;13(3):e1006219.
- 203 16. Cutler AJ et al. Capturing the systemic immune signature of a norovirus infection: an n-of-1 case  
204 study within a clinical trial. *Wellcome Open Res.* 2017;2:28.
- 205 17. Caballero IS et al. Lassa and Marburg viruses elicit distinct host transcriptional responses early after  
206 infection. *BMC Genomics* 2014;15(1):960.
- 207 18. Aschenbrenner AC et al. Disease severity-specific neutrophil signatures in blood transcriptomes  
208 stratify COVID-19 patients. *medRxiv* 2020;2020.07.07.20148395.
- 209 19. Chevrier S et al. A distinct innate immune signature marks progression from mild to severe COVID-  
210 19. *bioRxiv* 2020;2020.08.04.236315.
- 211 20. Bedin A-S et al. Monocyte CD169 expression as a biomarker in the early diagnosis of COVID-19.  
212 *medRxiv* 2020;2020.06.28.20141556.
- 213 21. Vetter P et al. Daily viral kinetics and innate and adaptive immune responses assessment in COVID-  
214 19: a case series. *medRxiv* 2020;2020.07.02.20143271.
- 215 22. Bourgoin P et al. A novel one-step extracellular staining for flow cytometry: Proof-of-concept on  
216 sepsis-related biomarkers. *J. Immunol. Methods* 2019;470:59–63.
- 217 23. Li S et al. Neutrophil CD64 expression as a biomarker in the early diagnosis of bacterial infection: a  
218 meta-analysis. *Int. J. Infect. Dis.* 2013;17(1):e12–e23.


- 219 24. Venet F, Lukaszewicz A-C, Payen D, Hotchkiss R, Monneret G. Monitoring the immune response in  
220 sepsis: a rational approach to administration of immunoadjuvant therapies. *Curr. Opin. Immunol.*  
221 2013;25(4):477–483.
- 222 25. Vitte J et al. A granulocytic signature identifies COVID-19 and its severity [Internet]. *J. Infect. Dis.*  
223 doi:10.1093/infdis/jiaa591
- 224 26. Bastard P et al. Auto-antibodies against type I IFNs in patients with life-threatening COVID-19.  
225 *Science* [published online ahead of print: September 24, 2020]; doi:10.1126/science.abd4585
- 226 27. Lee JS et al. Immunophenotyping of COVID-19 and influenza highlights the role of type I interferons  
227 in development of severe COVID-19. *Sci. Immunol.* 2020;5(49). doi:10.1126/sciimmunol.abd1554
- 228



**Figure 1. Expression of monocyte CD169 in CoVID-19 patients according to disease stage and SARS-CoV-2 RT-PCR results, compared to healthy blood donors.**

Box plots summarizing the level of CD169 index (ratio of monocyte vs lymphocyte signals) in Healthy Blood Donors (HBD, n=25, green dots) vs CoVID-19 patients at an early stage (A, black dots), late stage (B, blue dots), or asymptomatic (C, red dots). The blue line indicates the positivity threshold (3.5). Box-and-whisker plots come from the first to the third quartile and are cut by the median ; segments at the end are extreme values. These 3 CoVID-19 groups are further split according to the concomitant RT-PCR results. ROC curves are calculated for each (D), then sensitivity, specificity, PPV, and NPV at the 3.5 threshold value.

*AUC: Area Under the Curve; HBD: healthy blood donors; PPV: positive predictive value; NPV: negative predictive value*




**Figure 2. Correlation plot between concomitant SARS-CoV-2 RT-PCR Ct and CD169 index.**

Upregulation of monocyte CD169, expressed as CD169 index of monocyte-to-lymphocyte CD169 expression, was inversely correlated with SARS-CoV-2 Ct, itself inversely correlated with the patient's viral load.

*Ct, cycle threshold.*





**Figure 3. Expression of neutrophil CD64 and monocyte HLA-DR in CoVID-19 patients as a function of disease stage.**

Box plots summarizing the level of CD64 index (ratio of neutrophil vs lymphocyte signals) (A) and HLA-DR signal on monocytes (B) in CoVID-19 patients at an early stage, at a late stage, or asymptomatic, are shown. Box-and-whisker plots come from the first to the third quartile and are cut by the median; segments at the end are extreme values.

	<b>Early stage</b>	<b>Late stage</b>	<b>Asymptomatic</b>	<b>Total</b>	<b>p-value</b>
<b>n</b>	80	71	26	177	
<b>Age</b>	45.8 (19.4 – 81.9)	45.0 (22.3 – 68.7)	45.0 (20.5 – 61.3)	45.3 (20.5 – 69.6)	0.98
<b>M/F gender ratio</b>	0.82	0.61	1.89	0.82	0.056
<b>Time from symptom onset</b>	6 (2 – 14)	20 (15 – 37)	NA	16 (3 – 35)	10 <sup>-17</sup>
<b>Nb of SARS-CoV-2 RT-PCR positive</b>	52 (65 %)	5 (7.04 %)	9 (34.62 %)	76 (42.94 %)	10 <sup>-12</sup>
<b>SARS-CoV-2 RT-PCR Ct value</b>	27.25 (17.60 – 32.39)	30.20 (28.02 – 33.38)	27.70 (18.58 – 33.30)	27.65 (17.33 – 33.40)	0.21

**Table 1. Demography of the study cohort.**

Early stage is defined as the 14 first days from symptom onset; late stage is defined as 15 days or later after symptom onset. Data are presented as median and 5th-95 th percentiles.

*NA, not applicable; Nb: Number*